TABLE 1.

Antimicrobial susceptibility test of the enrolled isolates.

Isolate	MEM	IPM	FEP	CAZ	CSL	TZP	MNO	AMK	LVX	SXT	GSH
R1	≥16	≥16	≥32	≥64	≥64	≥128	8	4	≥8	≥320	6
R2	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	12
R3	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	6
R4	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	12
R5	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	≥320	12
R6	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	≥320	12
R7	≥16	≥16	≥32	≥64	≥64	≥128	8	≥64	≥8	≥320	12
R8	≥16	≥16	≥32	≥64	≥64	≥128	8	≤2	≥8	≥320	6
R9	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	12
R10	≥16	≥16	≥32	≥64	≥64	≥128	≥16	8	≥8	40	12
R11	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	12
R12	≥16	≥16	≥32	≥64	≥64	≥128	8	≥64	≥8	≥320	12
R13	≥16	≥16	≥32	32	≥64	≥128	2	≤2	≥8	2	12
R14	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≤2	≥8	≤20	12
R15	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≤20	12
R16	≥16	≥16	≥32	≥64	≥64	≥128	8	≥64	≥8	≥320	12
R17	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≥320	12
R18	≥16	≥16	≥32	≥64	≥64	≥128	2	≥64	≥8	≤20	12
R19	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	40	12
R20	≥16	≥16	≥32	≥64	≥64	≥128	8	≤2	≥8	≤20	12
R21	≥16	≥16	≥32	≥64	≥64	≥128	2	≥64	≥8	160	12
R22	≥16	≥16	≥32	≥64	≥64	≥128	8	≥64	≥8	≤20	12
R23	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≤20	12
R24	≥16	≥16	≥32	≥64	≥64	≥128	≥16	≥64	≥8	≤20	12
R25	≥16	≥16	≥32	≥64	≥64	≥128	8	≥64	≥8	≤20	12
R26	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	≤20	12
R27	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	≤20	6
R28	≥16	≥16	≥32	≥64	≥64	≥128	≥16	16	≥8	≥320	12
R29	≥16	≥16	≥32	≥64	≥64	≥128	4	≥64	≥8	≤20	12
R30	≥16	≥16	≥32	≥64	≥64	≥128	8	8	≥8	≤20	12

The MIC of various drugs, in mg/L (GSH, mg/mL). MEM, meropenem; IPM, imipenem; FEP, cefepime; CAZ, ceftazidime; CSL, cefoperazone-sulbactam; TZP, piperacillin-tazobactam; MNO, minocycline; AMK, amikacin; LVX, levofloxacin; SXY, trimethoprim-sulfamethoxazole; GSH, glutathione.